Edition:
United Kingdom

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

2.48USD
13 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.48
Open
$2.44
Day's High
$2.53
Day's Low
$2.44
Volume
3,605
Avg. Vol
21,799
52-wk High
$7.15
52-wk Low
$2.38

Latest Key Developments (Source: Significant Developments)

Sonoma Pharma Enters Into Deal For Distribution Of Dermatology Products Into Brazil
Tuesday, 5 Jun 2018 

June 5 (Reuters) - Sonoma Pharmaceuticals Inc ::U.SK, DERMATOLOGY ARM OF BRAZILIAN NC GROUP, AND SONOMA PHARMACEUTICALS ENTER INTO LICENSE AGREEMENT FOR EXCLUSIVE RIGHTS TO SONOMA’S DERMATOLOGY PRODUCTS IN BRAZIL.SONOMA PHARMACEUTICALS - ENTERED INTO DEAL FOR EXCLUSIVE DISTRIBUTION OF MULTIPLE SONOMA DERMATOLOGY PRODUCTS INTO BRAZIL.SONOMA PHARMACEUTICALS INC - FIRST PRODUCTS ARE EXPECTED TO HIT MARKET IN AUGUST 2018.  Full Article

Sonoma Pharma Gets Three New UAE Regulatory Approvals
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS.SONOMA PHARMACEUTICALS INC - ANTICIPATE LAUNCHING ALL THREE PRODUCTS ACROSS UNITED ARAB EMIRATES IN FEBRUARY 2018.  Full Article

Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS.  Full Article

Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Sonoma Pharmaceuticals Inc ::Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language.Approved Alevicyn dermal spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms​.  Full Article

Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million.Q2 revenue $4.3 million versus $2.8 million.Sonoma Pharmaceuticals qtrly loss per share from continuing operations​ $‍0.67.  Full Article

Sonoma Pharmaceuticals receives Brazilian approvals
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products.Sonoma Pharmaceuticals Inc - ‍is currently seeking to partner with a Brazilian healthcare co relative to licensing newly approved products.Sonoma Pharmaceuticals Inc - ‍issuance of regulatory approvals by Brazilian Ministério Da Saúde for 7 of co's dermatology products​.  Full Article

Oculus Innovative sciences Q1 revenue $3.8 million versus $3.7 million
Thursday, 28 Jul 2016 

Oculus Innovative Sciences Inc : Oculus innovative sciences reports financial results for first quarter of fiscal year 2017 .Q1 revenue $3.8 million versus $3.7 million.  Full Article

  • Previous
  • Next

Sonoma Pharmaceuticals Inc News

BRIEF-Sonoma Pharma Receives Four New Uae Regulatory Approvals That Include Acne And Anti-Fungal Products

* SONOMA PHARMACEUTICALS RECEIVES FOUR NEW UAE REGULATORY APPROVALS THAT INCLUDE ACNE AND ANTI-FUNGAL PRODUCTS

» More SNOA.OQ News

Earnings vs. Estimates

» More Financials